KP-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts.

Furuta S, Hori T, Ohyama T

Naunyn-Schmiedeberg's archives of pharmacology14 Jun 2006Cited by 1 (Europe PMC)

PMID16773386DOI10.1007/s00210-006-0079-9PepBankPUB-16773386

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In isolated rat hearts after ischemia/reperfusion, KP-102 at 0.1 nmol/l or more lowered LVEDP during reperfusion compared with controls.
In plain wordsIn isolated rat hearts, KP-102 lowered the pressure in the heart chamber during recovery compared with untreated hearts.
Peptide
GHRP-2
Outcome
DecreaseLVEDP during reperfusion
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
0.1 nmol/l or more · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
KP-102 at a dose of 0.1 nmol/l or more induced lower LVEDP and higher LVDP and gave higher +dP/dtmax and -dP/dtmax values during the reperfusion as compared with the control groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338601
02LabEx vivo tissueEfficacy outcome
In isolated rat hearts after ischemia/reperfusion, KP-102 at 0.1 nmol/l or more raised LVDP during reperfusion compared with controls.
In plain wordsIn isolated rat hearts, KP-102 improved the pressure the heart developed during recovery compared with untreated hearts.
Peptide
GHRP-2
Outcome
IncreaseLVDP during reperfusion
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
0.1 nmol/l or more · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
KP-102 at a dose of 0.1 nmol/l or more induced lower LVEDP and higher LVDP and gave higher +dP/dtmax and -dP/dtmax values during the reperfusion as compared with the control groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338602
03LabEx vivo tissueEfficacy outcome
In isolated rat hearts after ischemia/reperfusion, KP-102 at 0.1 nmol/l or more raised +dP/dtmax during reperfusion compared with controls.
In plain wordsIn isolated rat hearts, KP-102 improved the speed of heart contraction during recovery compared with untreated hearts.
Peptide
GHRP-2
Outcome
Increase+dP/dtmax during reperfusion
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
0.1 nmol/l or more · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
KP-102 at a dose of 0.1 nmol/l or more induced lower LVEDP and higher LVDP and gave higher +dP/dtmax and -dP/dtmax values during the reperfusion as compared with the control groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338603
04LabEx vivo tissueEfficacy outcome
In isolated rat hearts after ischemia/reperfusion, KP-102 at 0.1 nmol/l or more gave higher -dP/dtmax values during reperfusion than controls.
In plain wordsIn isolated rat hearts, KP-102 improved the speed of heart relaxation during recovery compared with untreated hearts.
Peptide
GHRP-2
Outcome
Increase-dP/dtmax during reperfusion
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
0.1 nmol/l or more · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
KP-102 at a dose of 0.1 nmol/l or more induced lower LVEDP and higher LVDP and gave higher +dP/dtmax and -dP/dtmax values during the reperfusion as compared with the control groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338604
05LabEx vivo tissueEfficacy outcome
In isolated rat hearts, KP-102 at 10 nmol/l suppressed the post-reperfusion rise in LVEDP, which returned to the preischemia level.
In plain wordsIn isolated rat hearts, a higher KP-102 concentration stopped the pressure rise after reperfusion and returned it to the starting level.
Peptide
GHRP-2
Outcome
DecreaseLVEDP restoration after reperfusion at 10 nmol/l
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
10 nmol/l · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
In particular, KP-102 at 10 nmol/l clearly suppressed the increase in the LVEDP after reperfusion; eventually, the LVEDP was restored to the preischemia level.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338605
06LabEx vivo tissueEfficacy outcome
At 40 min of reperfusion in isolated rat hearts, KP-102 at 10 nmol/l increased LVDP compared with control.
In plain wordsIn isolated rat hearts, 10 nmol/l KP-102 raised the developed heart pressure at 40 minutes of recovery compared with control.
Peptide
GHRP-2
Outcome
IncreaseLVDP at 40 min of reperfusion at 10 nmol/l
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
10 nmol/l · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
At 40 min of reperfusion, 10 nmol/l KP-102 noticeably increased the LVDP, +dP/dtmax, and -dP/dtmax, as compared with the control.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338606
07LabEx vivo tissueEfficacy outcome
At 40 min of reperfusion in isolated rat hearts, KP-102 at 10 nmol/l increased +dP/dtmax compared with control.
In plain wordsIn isolated rat hearts, 10 nmol/l KP-102 raised the speed of contraction at 40 minutes of recovery compared with control.
Peptide
GHRP-2
Outcome
Increase+dP/dtmax at 40 min of reperfusion at 10 nmol/l
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
10 nmol/l · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
At 40 min of reperfusion, 10 nmol/l KP-102 noticeably increased the LVDP, +dP/dtmax, and -dP/dtmax, as compared with the control.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338607
08LabEx vivo tissueEfficacy outcome
At 40 min of reperfusion in isolated rat hearts, KP-102 at 10 nmol/l increased -dP/dtmax compared with control.
In plain wordsIn isolated rat hearts, 10 nmol/l KP-102 raised the speed of relaxation at 40 minutes of recovery compared with control.
Peptide
GHRP-2
Outcome
Increase-dP/dtmax at 40 min of reperfusion at 10 nmol/l
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
10 nmol/l · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
At 40 min of reperfusion, 10 nmol/l KP-102 noticeably increased the LVDP, +dP/dtmax, and -dP/dtmax, as compared with the control.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338608
09LabEx vivo tissueSafety outcome
In isolated rat hearts, KP-102 had no effect on heart rate throughout the experiment.
In plain wordsIn isolated rat hearts, KP-102 did not change the heart rate.
Peptide
GHRP-2
Outcome
No significant changeHeart rate
Study
ratn: not reported in source
Isolated Wistar rat hearts, Langendorff ischemia/reperfusion
Comparator
Control
Outcome group
Heart function · Cardiovascular
Studied dose
0.1-10 nmol/l · From 15 min before ischemia until the end of the experiment, except during ischemiaAs given in this study (rat).
Source sentences
Summary
KP-102 had no effect on the HR throughout the experiment.
2 context sentences(design, population, supporting numbers)
Summary · context
Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion.
Summary · context
The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end of the experiment, with the exception of the ischemia period.
Report a problemFND-1677338609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.